An interventional study of Ductal Arterial Stent and Systemic-to-Pulmonary Artery Shunt in Congenital Heart Disease in Children, sponsored by Carelon Research. Active, not recruiting at 24 sites in 2 countries. Open to participants aged 1 Day to 30 Days. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Carelon Research · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Heart Defects, Congenital by Carelon Research — 2 open to participants now, 4 under way, 1 of them phase 3. Heart Defects, Congenital · Carelon Research.
Among the 10 studies in Heart Defects, Congenital by Carelon Research, this one is one of 2 that started in 2022, is one of 5 with no phase, and was the 8th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →2 of the 10 studies in Heart Defects, Congenital by Carelon Research are open now, in 1 country. Recruiting first, the newest first:
Carelon Research · Sites in United States
Ages 18+
Carelon Research · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 1 Day to 30 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 1
First in 2003; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 177 across the 8 interventional studies, 410 across the 2 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Carelon Research is the lead sponsor of 59 studies on the registry; 4 are open to participants now.
1 of the studies in Heart Defects, Congenital by Carelon Research that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05268094Carelon ResearchComparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial) | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Heart Defects, Congenital by Carelon Research, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
COMPASS is a prospective multicenter randomized interventional trial. Participants with ductal-dependent pulmonary blood flow will be randomized to receive either a systemic-to-pulmonary artery shunt or ductal artery stent. Block randomization will be performed by center and by single vs. two ventricle status. Participants will be followed through the first year of life.
In neonates with ductal-dependent blood flow there remains valid uncertainty regarding the comparative benefits of ductal artery stent (DAS) with the traditional systemic-to-pulmonary artery shunt (SPS) palliation due to the lack of previous multicenter studies. COMPASS is a prospective multicenter randomized interventional trial where participants will be randomized to receive either an SPS or DAS to compare rates of a composite major morbidity/mortality endpoint in the first year of life. The study objectives are to perform an intention-to-treat analysis of participants' outcomes, and to describe the failure rate for neonatal candidates for DAS and the impact of this failure on the post-SPS course. Participants will be followed through the first year of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Any patient for whom the clinical decision at the enrolling center is that an initial intervention other than DAS or SPS is indicated (e.g., Right Ventricle-Pulmonary Artery (RV-PA) conduit, Right Ventricular Outflow Tract (RVOT) stent, primary complete anatomic repair, etc.).
2. Pulmonary Atresia with Intact Ventricular Septum (PA/IVS) where Right Ventricle (RV) decompression is planned.
3. Presence of MAPCAs: defined as an aortopulmonary collateral that is expected to require unifocalization.
4. Non-confluent Pulmonary Arteries (i.e., isolated Pulmonary Artery (PA) of ductal origin).
5. Acutely jeopardized branch Pulmonary Arteries (>75% narrowing of proximal PA based on screening cross sectional imaging [Computed Tomography Angiography (CTA) or cardiovascular Magnetic Resonance (cMR)]).
6. Bilateral Patent Ductus Arteriosis (PDA). 7. Patient who, at the time of enrollment, is deemed not to be a candidate for eventual Glenn or Complete Surgical Repair (CSR) for any reason.
8. Birth weight \<2.0 kg. 9. Gestational age \<34 weeks at birth. 10. Patient for whom additional intervention is expected concomitant with, or prior to, DAS or SPS (e.g., atrial septostomy, aortic arch intervention, or RV outflow tract intervention) - except for branch PA arterioplasty or stent/balloon angioplasty.
11. Major co-morbidities which, in the opinion of the investigator, would negatively alter expected 1-year survival (e.g., intracranial hemorrhage, renal failure, etc.).
12. Specific known genetic anomaly which, in the opinion of the investigator, would be expected to significantly alter clinical course in the first year of life (e.g., Trisomy 13/18, CHARGE, VACTERL).
13. Patient who does not plan to return to the enrolling center or another participating center for Glenn/CSR.
Transcatheter ductal artery shunt will be placed by the interventional team. Drug-eluting coronary stent brand, length, and diameter are determined by the interventional team.
Device: Ductal Arterial Stent
Surgical systemic-to-pulmonary artery shunt performed by the interventional team. SPS diameter, length, and material will be determined by the surgeon performing the intervention.
Procedure: Systemic-to-Pulmonary Artery Shunt
Drug-eluting ductal arterial stents will be placed by transcatheter method.
Also known as: Medtronic Resolute Onyx, Boston Scientific Promus Elite/Premier, Boston Scientific Synergy, Cordis Elunir, Abbott Xience
A surgical connection will be made between a systemic artery and the pulmonary artery.
Morbidity and/or Mortality Endpoint
Rates of a composite major morbidity and/or mortality endpoint in the first year of life will be compared between neonates with ductal-dependent pulmonary blood flow randomized to receive either DAS or SPS as the initial palliation.
Time frame: 1 year
Global Rank Score
All participants will be assigned a Global Rank Score, which is a rank based on a pre-specified hierarchical ranking of outcomes. This combines various endpoints into a single quantifiable endpoint with weighting of the severity of the component endpoints, and allows for the inclusion of endpoints of different forms. Global rank scores will range from 1-7.
Time frame: 1 year
Freedom from Adverse Events
Safety, defined as freedom from procedural adverse events and complications, will be tracked and evaluated.
Time frame: 1 year
Days Alive out of Hospital
Days alive out of the hospital represents a patient-centered outcome, and functions as a composite endpoint.
Time frame: 1 year
Plan to share: Yes — All individual participant data collected by the Data Coordinating Center will be shared after posting of results and main study results publication.
Supporting information: Study protocol, Informed consent form
Time frame: Protocol and Informed Consent Form will be shared within 12 months of publication of study results. Public Use Dataset will be made available after publication, timeframe to be decided.
Access criteria: Protocol and Informed Consent Form will be made available with results on clinicaltrials.gov. Public Use Dataset will be available on the Pediatric Heart Network public website and may be used in accordance with Pediatric Heart Network governance.
Data sharing details ↗ · www.pediatricheartnetwork.org
Started Jun 2022 (actual). Primary completion is estimated for Sep 2027, 62 months after the start.
Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 62 months is above that.
Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carelon Research